Efficacy and Safety of Tirzepatide in Adults With Type 1 Diabetes: A Proof of Concept Observational Study

Feb 6, 2024Journal of diabetes science and technology

Tirzepatide's effectiveness and safety in adults with type 1 diabetes

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Tirzepatide led to a significant reduction in hemoglobin A1c by 0.59% and body weight by 10.1% at 8 months in adults with type 1 diabetes.

The mean age of participants was 42 years, with a mean body mass index of 36.7 kg/m².
HbA1c levels decreased by 0.45% at 3 months and 0.59% at 8 months.
Body weight reduced by 3.4% at 3 months, 10.5% at 6 months, and 10.1% at 8 months.
Time in target glucose range increased by 12.6% and time in tight target range increased by 10.7% at 3 months.
Time above range decreased by 12.6% at 3 months, with these changes sustained over 8 months.
The medication was relatively safe and well tolerated, with only 2 patients discontinuing treatment.

AI simplified

BACKGROUND: Tirzepatide is approved by the United States Food and Drug Administration (FDA) for the management of type 2 diabetes. The efficacy and safety of this drug have not been studied in people with type 1 diabetes (T1D).

METHODS: In this single-center, retrospective, observational study, hemoglobin A1c (HbA1c), weight, body mass index (BMI), and continuous glucose monitoring (CGM) data were collected from electronic health records of adults with T1D at initiation of tirzepatide and at subsequent clinic visits over 8 months. Primary outcomes were reduction in HbA1c and percent change in body weight and secondary outcomes were change in CGM metrics and BMI over 8 months from baseline.

RESULTS: The mean (±SD) age of the 26 adults (54% female) with T1D was 42 ± 8 years with a mean BMI of 36.7 ± 5.3 kg/m. There was significant reduction in HbA1c by 0.45% at 3 months and 0.59% at 8 months, and a significant reduction in body weight by 3.4%, 10.5%, and 10.1% at 3, 6, and 8 months after starting tirzepatide. Time in target range (TIR = 70-180 mg/dL) and time in tight target range (TITR = 70-140 mg/dL) increased (+12.6%,= .002; +10.7%,= .0016, respectively) and time above range (TAR >180 mg/dL) decreased (-12.6%,= .002) at 3 months, and these changes were sustained over 8 months. The drug was relatively safe and well tolerated with only 2 patients discontinuing the medication. 2P P P

CONCLUSIONS: Tirzepatide significantly reduced HbA1c and body weight in adults with T1D. A randomized controlled trial is needed to establish efficacy and safety of this drug in T1D.

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text (XML) ↗View full text ↗

Efficacy and Safety of Tirzepatide in Adults With Type 1 Diabetes: A Proof of Concept Observational Study

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief